Sponsor:
Massachusetts General Hospital
Code:
NCT06538311
Conditions
Alzheimer Disease
Mild Cognitive Impairment
Logopenic Progressive Aphasia
Amnestic Symptoms
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Accepted
Interventions
Active rTMS
Sham rTMS
Brief summary:
Conditions
Alzheimer Disease
Mild Cognitive Impairment
Logopenic Progressive Aphasia
Amnestic Symptoms
Study ID
NCT06538311
Start date
May 1, 2023
Status verified date
Feb, 2026
Completion date
Mar 31, 2027
Anticipated
Primary completion date
Mar 31, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Accepted
Enrollment
30 participants
Anticipated
Intervention Model
Single group
Primary purpose
Other
Arms
experimental: AD, aMCI, lvPPA patients, and preclinical AD
Interventions
Active rTMS
Sham rTMS
Primary outcome measure
Central contacts
Locations
Massachusetts General Hospital
Recruiting
Boston, Massachusetts, United States, 02129
Contacts
Alexandra Touroutoglou, PhD
atouroutoglou@mgh.harvard.eduPrincipal Investigator:
Alexandra Touroutoglou, PhD
Sponsor
Massachusetts General Hospital
Last update posted
May 6, 2026
Last verified
Feb, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-05-06.